Loading…
Loading…
HAVLF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for HAVLF and 80,000+ other tickers.
See exactly how HAVLF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for HAVLF and 80,000+ other tickers.
HAVN Life Sciences Inc. is a biotechnology firm that specializes in the research and innovation of psychotropic compounds derived from botanical and fungal organisms. The company is also dedicated to establishing standardized, quality-controlled methodologies for extracting these psychoactive molecules, with a specific focus on Psilocybe mushroom species and their key constituents such as psilocybin, psilocin, and baeocystin. Furthermore, it develops natural health products utilizing unregulated ingredients. Founded in 2020, HAVN Life Sciences' operations are headquartered in Richmond, Canada.
CEO, Tim Moore will share recent partnership and distribution news and a roadmap for the Company's plans for the next quarterVancouver, British Columbia--(Newsfile Corp. - June 6, 2022) - Havn Life Sciences Inc. (CSE: HAVN) (OTC Pink: HAVLF) (FSE: 5NP) (the "Company" or "HAVN Life"), a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and cognitive function, is announcing that CEO, Tim Moore will be presenting at the LD Micro Invitational XII, taking place June 7-9, 2022 at the Four Seasons Westlake Village in...
VANCOUVER, BC / ACCESSWIRE / April 30, 2022 / HAVN Life Sciences Inc. (CSE:HAVN) (OTC:HAVLF) (FSE:5NP) , a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as potential APIs to support brain health and cognitive function, today announced that it will be presenting at the Planet MicroCap Showcase 2022 at the Bally's Hotel & Casino in Las Vegas, NV on Wednesday, May 4, 2022 at 9:00 a.m. PST. Tim Moore, CEO of HAVN Life Sciences Inc.,will be hosting the presentation and answering questions from investors.
The partnership is a integral step in the The Company's path to market in the U.S., achieving one of its most important milestones to-date VANCOUVER, BC / ACCESSWIRE / September 23, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life") a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and enhance the capabilities of the mind, is thrilled to announce a partnership with California-based Mycrodose Therapeutics, one of only a few private companies that has been granted a Schedule I License to research four (4) psychedelic compounds including psilocybin, MDMA, DMT, & LSD by the United States Drug Enforcement Agency (DEA). HAVN Life will work with its partners to export their naturally derived psilocybin to Mycrodose Therapeutics, where it will be used in the development of advanced drug delivery (ADD) systems to treat mental health and cognitive degenerative diseases, as well as be distributed to appropriately licenced customers in the U.S. "We are excited to have forged this partnership with Mycrodose Therapeutics, building an important link in our supply chain to service our Supply Agreement partners in the US," says HAVN Life CEO Tim Moore.
VANCOUVER, BC / ACCESSWIRE / September 21, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of active pharmaceutical ingredients that support brain health and enhance the capabilities of the mind, is pleased to announce their partnership with Horizon Grocery + Wellness, Western Canada's leading distributor of organic and natural foods, natural personal care items, and nutritional health supplements (the "Distribution Deal"). Horizon will distribute the full portfolio of HAVN Life's line natural health products, which launched this June.
The partnership will further industry growth for naturally derived psilocybin VANCOUVER, BC / ACCESSWIRE / August 25, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life") a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and enhance the capabilities of the mind, recently signed an agreement to supply naturally-derived psilocybin to Mycotopia Therapies (OTC: TPIA) for their psychedelic therapies. Headquartered in Florida, Mycotopia Therapies uses psilocybin to treat people dealing with anxiety, depression, bipolar disorders, PTSD, ADHD, autism, and addictions.